Close

pp50

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

CMV pp50 peptide VTEHDTLLY (HLA-A*0101) for stimulation of T-cells. Single peptide (VTEHDTLLY) for stimulation of human CMV pp50-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0101 allele. Lyophilized powder. Purity> 80 %, endotoxin free.

Associated Disease
  • CMV disease
  • TCR Vector Products

  • TCR Viral Particles

Loading...
  • Target Species:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-L096 Human anti-pp50 (VTEHDTLLY) T Cell Receptor, pMP71 CMV Human VTEHDTLLY HLA-A1 retroviral vector   Add to Cart   Datasheet
TCR-L095Z Human anti-pp50 (aa245-253) T cell receptor (Codon optimized and cysteine modified), pCDTCR1 CMV Human VTEHDTLLY HLA-A1 Lentiviral   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.